China Resources Boya Bio-pharmaceutical Group Co., Ltd.: history, ownership, mission, how it works & makes money

From its founding in 1993 to its Shenzhen listing under ticker 300294 in 2009, China Resources Boya Bio-pharmaceutical Group Co., Ltd. has evolved into a plasma-focused pharmaceutical player-rebranding in 2017 after integration with China Resources Pharmaceutical Group and expanding through the 2014 acquisition of Green Cross (China) to boost plasma collection; today the company reports 1.96 billion yuan in 2025 revenue and a net profit of 327.25 million yuan, operates 21 plasma collection stations (20 active) with a recorded collection of 522.04 tonnes (up 11.71% year‑on‑year), employs 1,938 people, and carries a market capitalization of about 11.80 billion yuan as of December 4, 2025-backed by China Resources Pharmaceutical Group's ~41.79% stake and bolstered by strategic moves such as the May 2025 additional purchase of 6,050,900 shares and the May 2025 market approval of 10% immunoglobulin, positioning the company to capture opportunities as China's blood products market expands from ~60 billion yuan in 2024 toward an estimated 100 billion by 2030 while revenue streams span human coagulation and immunoglobulins, non‑blood injectables, and R&D-driven anti‑infective, diabetes and cardiovascular drugs.

China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ): Intro

• Founded: 1993
• Shenzhen Stock Exchange listing: 2009 (Ticker: 300294)
• Major acquisition: Green Cross (China) Biopharmaceutical Co., Ltd. in 2014 (expanded plasma collection & processing)
• Rebrand/integration: 2017 - renamed to reflect integration into China Resources Pharmaceutical Group
• Market capitalization: ≈14.29 billion yuan (2020)
• Employees: 1,938 (by 2025)

• Plasma collection & fractionation: sourcing plasma (in-house and via acquisitions), producing albumin, immunoglobulins, coagulation factors and other plasma-derived therapies.
• Manufacturing: GMP-compliant production lines for blood-derived and non-blood biologics and sterile injectables.
• Commercialization & distribution: national sales network to hospitals, CDCs and retail/wholesale pharmaceutical channels in China; selected exports.
• R&D and product pipeline: improvement of fractionation yields, product formulation, clinical development for new biologics and biosimilars.
• Contract manufacturing & toll processing: third-party production services leveraging plasma-processing capacity.

• Primary revenue: sales of plasma-derived products (human albumin, intravenous immunoglobulin (IVIG), coagulation factors) - typically higher ASPs and gross margins versus commodity generics.
• Secondary revenue: sales of non-blood pharmaceuticals and sterile injectables, distribution margins, contract manufacturing fees and government procurement contracts.
• Cost profile: raw material (plasma) procurement, cold-chain logistics, GMP production costs, quality control and regulatory compliance; CAPEX-heavy for fractionation and bioprocessing capacity.
• Pricing & reimbursement: dependent on National Reimbursement Drug List (NRDL) inclusion, hospital procurement tenders and provincial purchasing policies in China.

• Plasma supply expansion: post-2014 acquisition increased plasma collection footprint and supply security to support higher output of high-margin biologics.
• Capacity investments: ongoing upgrades to fractionation, purification and sterile manufacturing lines to improve yields and regulatory compliance.
• Integration benefits: access to China Resources Pharmaceutical Group channels and procurement scale following 2017 rebrand/integration.

• Plasma supply volatility and donor concentration risk.
• Regulatory oversight and safety standards for blood products (stringent inspections, lot-release requirements).
• Price pressure from procurement tenders and potential biosimilar competition in non-blood segments.
• Need for continuous CAPEX to meet GMP and capacity requirements.

China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ): History

• Founding and expansion: grew from manufacturing APIs to a broader portfolio including generic and specialty formulations.
• Strategic alignment: deep integration with parent China Resources Pharmaceutical Group for procurement, distribution and financing.
• Recent investment activity: in May 2025, China Resources Medicine Holdings acquired an additional 6,050,900 shares, increasing its effective control and signaling confidence in future prospects.

• Major shareholder: China Resources Pharmaceutical Group Limited held approximately 41.79% of total share capital and 41.79% of voting rights as of December 2025.
• Public float and liquidity: remaining shares trade on the Shenzhen Stock Exchange, enabling market pricing and investor participation.
• Market capitalization: approximately ¥11.80 billion as of December 4, 2025.
• Share price dynamics: 52-week trading range between ¥22.84 and ¥31.65, reflecting sector cycles and investor sentiment.

• Manufacturing: produces APIs and finished-dose products sold to hospitals, distributors and exporters.
• Contract manufacturing & OEM: provides production services for third parties, leveraging scale and quality certifications.
• Product portfolio: revenues derived from generics, specialty drugs, and biologics with pricing and volume mix determining margins.
• Distribution synergy: benefits from China Resources' nationwide distribution channels, improving market access and working-capital terms.

China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ): Ownership Structure

• Mission and Values: committed to supplying safe, effective blood products and accessible therapeutics to the Chinese population.
• Innovation focus: R&D priority areas include anti-infective agents, diabetes care, and cardiovascular drugs to target major disease burdens in China.
• Sustainability: efficient plasma collection, utilization, and cold-chain logistics to secure steady blood-product supply.
• Patient-centricity and ethics: improving outcomes through quality products, regulatory compliance, and transparent operations.
• Collaboration: partnerships with hospitals, plasma centers, and research institutes to accelerate development and distribution.

• Plasma collection and processing: revenue from plasma-derived biologics-albumin, IVIG, and coagulation factors-produced via in-house fractionation or contracted partners.
• Proprietary and licensed drugs: sales of anti-infective, anti-diabetic, and cardiovascular pharmaceuticals through hospital channels and retail pharmacies.
• Contract manufacturing & partnerships: fee income and margin from processing services, technology transfers, and joint development with domestic healthcare institutions.
• Scale and margin drivers: higher plasma yield, improved fractionation efficiency, volume contracts with hospitals, and successful commercialization of new drug launches.

• Expand plasma collection network and optimize utilization to secure product supply and lower unit costs.
• Advance clinical pipelines in anti-infective, diabetes, and cardiovascular areas to capture large patient populations.
• Strengthen hospital and institutional collaborations to broaden market access and accelerate uptake of new therapies.
• Maintain compliance and ethical standards to protect brand trust and ensure regulatory approval pathways.

China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ): Mission and Values

• Plasma collection network: operates 21 plasma collection stations, with 20 currently operational, forming the feedstock backbone for manufacturing plasma-derived therapeutics.
• Plasma volumes: achieved a plasma collection volume of 522.04 tonnes in the most recent reporting period, an 11.71% year-on-year increase, evidencing expanding collection capability and donor engagement.
• Manufacturing flow: collected plasma is transported to fractionation and purification facilities where immunoglobulins, albumin, coagulation factor products and other plasma-derived biologics are produced under GMP conditions.
• Distribution and sales: finished products are distributed to hospitals, clinical partners, and pharmaceutical distributors domestically with marketing and reimbursement strategies aligned to China's healthcare system.
• R&D and quality control: maintains laboratories for process development, quality assurance and regulatory compliance to support pipeline expansion and post-market surveillance.

• Primary revenue from sale of plasma-derived products (human albumin, immunoglobulins, coagulation factors) and related clinical services.
• Scale effects from increased plasma collection volumes improve gross margins by spreading fixed processing costs over larger output.
• Operational leverage from network optimization-bringing dormant stations online or expanding throughput at existing sites drives incremental revenue without proportional fixed-cost increases.
• Regulatory approvals and inclusion in provincial/national procurement lists support consistent demand and pricing power.

• Diversified plasma supply network reduces single-site dependency and improves resilience against localized disruptions.
• Volume growth (522.04 tonnes, +11.71% YoY) supports higher production capacity and potential margin expansion.
• Scale and compliance with GMP and regulatory standards position the company to compete in China's growing plasma-derived therapeutics market.

• Publicly traded on Shenzhen Stock Exchange (300294.SZ), enabling market valuation and liquidity-market cap ~11.80 billion yuan as of Dec 4, 2025.
• Detailed investor and ownership insights available here: Exploring China Resources Boya Bio-pharmaceutical Group Co., Ltd. Investor Profile: Who's Buying and Why?

China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ): How It Works

• Primary manufacturing: plasma fractionation and purification lines for coagulation factors, albumin, immunoglobulins, and other plasma-derived therapeutics.
• R&D and pipeline: in-house discovery and formulation capabilities for anti-infective, diabetes, and cardiovascular drugs, plus process development for biologics.
• Distribution: direct sales teams to hospitals and institutional buyers, partnerships with regional pharmacy chains, and logistics for cold-chain biological distribution.
• Vertical integration: ownership or strategic control of plasma collection centers, manufacturing sites, and commercialization channels to capture margin across the value chain.

• Blood products (major revenue driver): human coagulation factors, human prothrombin complex, human fibrinogen, human albumin, intravenous human immunoglobulin (IVIG), rabies immunoglobulin.
• Non-blood biologics and injectables: bone peptide, oxytocin, heparin sodium, posterior pituitary extracts and related formulations.
• Small-molecule therapeutics and specialty drugs: anti-infective agents, antidiabetic medications, cardiovascular drugs developed or licensed by the company.
• Service and distribution income: sales distribution fees, contract manufacturing revenues, and revenues from acquired subsidiaries.

• High-demand, essential blood products (e.g., IVIG, albumin) provide recurring institutional contracts and stable base revenue.
• Diversification into non-blood biologics and specialty drugs reduces dependence on plasma product cycles and regulatory risks.
• Acquisitions and strategic M&A (e.g., acquisition of Green Cross (China) Biopharmaceutical Co., Ltd.) expanded production capacity, product lines, and market access, increasing cross-selling opportunities.
• Focus on quality and regulatory compliance supports premium pricing in hospital tender markets and fosters long-term procurement relationships.

• Direct product sales: hospitals and blood banks purchase finished plasma-derived products and injectables via tenders and long-term supply agreements.
• Hospital tender wins: institutional bidding for IVIG, albumin, coagulation factors yields large-volume, recurring orders.
• Pharmacy and retail channels: non-blood injectable products and select small-molecule drugs sold through pharmacy networks.
• Contract manufacturing and CMO services: third-party production for other biopharma companies and OEM agreements generate additional manufacturing margin.
• Post-acquisition assimilation: acquired companies' catalogs and customer bases are integrated to broaden offerings and increase sales cross-sell.

• Pipeline commercialization: progressing anti-infective, diabetes, and cardiovascular candidates to market increases higher-margin proprietary revenues.
• Capacity expansion: added fractionation and fill-finish lines raise output for high-demand products such as IVIG and albumin.
• Quality and compliance: adherence to GMP, cold-chain logistics, and pharmacovigilance maintains market access and price premiums.
• Geographic expansion: leveraging distribution networks and acquisitions to penetrate second- and third-tier cities and institutional buyers.

China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ): How It Makes Money

• Founded as part of the China Resources group, China Resources Boya has evolved into a vertically integrated plasma-derived biopharma company focused on blood products and related biologics.
• Listed on the Shenzhen Stock Exchange (300294.SZ) and majority-influenced by state-owned China Resources parent holdings, with professional management overseeing operations and expansion of plasma-collection and manufacturing capacity.

• Mission: supply safe, high-quality plasma-derived therapeutics and expand access to innovative blood products across China.
• Strategic priorities: grow plasma collection network, obtain regulatory approvals for higher-value products (e.g., 10% immunoglobulin), and scale manufacturing to meet domestic demand.

• Primary inputs: plasma collected from company-managed collection stations and contracted centers.
• Processing: fractionation and purification at GMP-compliant facilities to produce immunoglobulins, albumin, clotting factors, and other plasma-derived medicines.
• Distribution: sales to hospitals, blood product distributors, and specialty clinics across China; cold-chain logistics and quality control are key revenue enablers.
• R&D & regulatory: product development and securing approvals (e.g., 10% immunoglobulin approval in May 2025) to move up the value chain and command higher margins.

• Sales of plasma-derived therapeutics (immunoglobulins, albumin, clotting factors).
• Contract plasma collection and service fees from partner centers.
• Premium pricing for new, higher-concentration formulations (e.g., 10% immunoglobulin) and proprietary processes.
• Potential future licensing or co-development deals as product portfolio and approvals expand.

• Position: a significant national player in plasma-derived products with growing scale-backed by state-affiliated ownership and expanding collection capacity.
• Market opportunity: China blood products market ~60 billion yuan in 2024, forecast to reach ~100 billion yuan by 2030, creating a large addressable market.
• Growth drivers: scaling plasma collection stations, commercialization of 10% immunoglobulin, pipeline product approvals, and higher utilization of existing manufacturing capacity.
• Risks: regulatory oversight, donor recruitment and retention, pricing pressure, and competition from established domestic and international plasma product manufacturers.